BerGenBio ASA (BRRGF) Stock Price, News & Analysis

Company Overview

BerGenBio ASA is a clinical-stage biopharmaceutical company headquartered in Bergen, Norway, specializing in the discovery and development of novel medicines that target the AXL receptor tyrosine kinase. Established in 2003 as a spin-out from the University of Bergen, the company aims to address unmet medical needs in oncology and fibrotic diseases through precision medicine approaches and biomarkers.

The company’s lead product candidate, bemcentinib (BGB324), is an oral, selective AXL inhibitor in Phase II/III clinical trials, designed to enhance immune response and overcome resistance to existing therapies. BerGenBio also maintains an earlier-stage pipeline focused on next-generation AXL inhibitors and combination strategies in solid tumors, hematological malignancies and fibrotic conditions. Collaborations with global partners have supported clinical development programs across multiple indications.

BerGenBio operates research facilities in Norway and maintains clinical trial offices in Europe, North America and Asia. Its multidisciplinary team includes scientists, clinical development experts and regulatory professionals driving early research through late-stage trials. Under the leadership of CEO Richard Godfrey and a board of experienced industry executives, the company continues to expand its strategic collaborations and prepare for potential regulatory submissions.

Key Stats

• Today's Range: $250.00 to $250.00
• 50-Day Range: $250.00 to $250.00
• 52-Week Range: $0.03 to $0.03
• Volume: N/A
• Average Volume: 200 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRRGF Stock Analysis - Frequently Asked Questions

How have BRRGF shares performed this year?

BerGenBio ASA's stock was trading at $2.50 at the beginning of 2025. Since then, BRRGF shares have increased by 9,900.0% and is now trading at $250.00.

How do I buy shares of BerGenBio ASA?

Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BRRGF
• CIK: N/A
• Web: www.bergenbio.com
• Phone: 47 53 50 15 64
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A